In the last decade, researchers have discovered 10 different pathways and paradigms to interrupt a cancer, Herbst explains. Immunotherapy has been a key player in targeting some of these pathways, but there are others that required novel targeted agents.

The Lung-MAP trial, for example, is an umbrella trial of 4 to 5 agents against specific molecular targets, Herbst says, adding it is being conducted in nearly 700 centers. This should be a paradigm for how researchers identify targets and explore agents through phase I studies to demonstrate activity. This will also help researchers conduct phase II studies in a cooperative way, he adds.

In the last decade, researchers have discovered 10 different pathways and paradigms to interrupt a cancer, Herbst explains. Immunotherapy has been a key player in targeting some of these pathways, but there are others that required novel targeted agents.

The Lung-MAP trial, for example, is an umbrella trial of 4 to 5 agents against specific molecular targets, Herbst says, adding it is being conducted in nearly 700 centers. This should be a paradigm for how researchers identify targets and explore agents through phase I studies to demonstrate activity. This will also help researchers conduct phase II studies in a cooperative way, he adds.